08/06/2003 14:49 FAX 16175265

## HALE AND DORR LLP

haledorr.com

60 STATE STREET . BOSTON, MA 02109 617-526-6000 • PAX 617-526-5000

FAX RECEIVED

AUG 1 3 2003

Total Number of Pages: 5

Fax / Phone:

GROUP 1600

To:

Philip Gambel, Ph.D.

U.S. Patent and Trademark Office

**(703) 746-7293 / (703) 308-3997** 

From: Joseph Koipally

617-526-6026

Date: August 6, 2003

Note:

Dear Examiner Gambel:

As per our telephone message of this afternoon, please find attached amended claims for USSN: 09/350,202 and USSN: 09/349,915.

Thank you.

Sincerely,

Joseph Koipally

<u>Unofficial</u>

This facsimile transmission is confidential and may be privileged. If you are not the intended recipient, please immediately call the sender or, if the sender is not available, call 617-526-5413, and destroy all copies of this transmission. If the transmission is incomplete or illegible, please call the sender or, if the sender is not available, call 617-526-5413. Thank you.

Client Matter Number: 36119-125

Return To:

2924

Transmitted by:


BOSTON

MUNICH NEW YORK

WALTHAM

WASHINGTON

LONDON



USSN: 09/350,202

## DRAFT

## PROPOSED AMENDMENTS TO USSN: 09/350,202

Claim 50. (Currently Amended): A method for inducing ex vivo proliferation of a population of T cells, comprising:

contacting a population of T cells ex vivo with a solid phase surface having covalently attached thereto:

- (a) a first agent which provides a primary activation signal in the T cells, thereby activating the T cells and
- (b) a second agent an anti-CD28 antibody which stimulates an accessory molecule on the surface of the T cells, thereby stimulating the activated T cells, wherein the first agent and second agent the anti-CD28 antibody are covalently attached to the same solid phase surface,

the first <u>agent</u> and <del>second agents</del> the anti-CD28 antibody thereby inducing the population of T cells to proliferate.

Claim 51. (Previously Added): The method of claim 50, wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

Claim 52. (Previously Added): The method of claim 50, wherein the first agent is an anti-CD3 antibody.

Claim 53. (Previously Added): The method of claim 52, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

Claim 54. (Previously Presented): The method of claim 50, wherein the accessory molecule on the T cell is CD28.

Claim 55. (Cancelled): The method of claim 54, wherein the second agent is an anti-CD28 antibody.

Claim 56. (Previously Cancelled)